Abstract 1512P
Background
Life expectancy has currently increased and pancreaticoduodenectomy (PD) is being performed more frequently on elderly patients in Japan. Surgical treatment for pancreatic ductal adenocarcinoma (PDAC) in patients over 80 years old is increasingly accepted, although it may lead to a decline in quality of life after surgery. Currently, there are no definitive indications for PD in octogenarians. This study aims to examine the surgical indications for PD in this age group, focusing on clinical background and perioperative and postoperative outcomes.
Methods
This retrospective analysis included patients with PDAC who underwent PD between 2012 and 2022. Patients aged ≥80 years were categorized as the Elderly (E) group, while those <80 years were classified as the Non-elderly (N) group. We compared clinical backgrounds, perioperative, and postoperative outcomes between the groups.
Results
PD was performed on 147 patients with PDAC. The median age was 71 years (range 45-85). Twenty-two patients (15.0%) were in the E group and 125 (85.0%) in the N group. The median Charlson comorbidity index (CCI) was significantly higher in the E group (6, range 5-10) compared to the N group (4, range 1-11; p
Conclusions
PD could be safely performed in elderly patients in good physical condition, with the survival benefit of PD for PDAC appearing as promising in elderly patients as in non-elderly patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Keio University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1475TiP - Fruquintinib in combination with sintilimab and CAPEOX as first-line treatment for advanced G/GEJ cancer: A phase Ib/II clinical trial (FUNCTION)
Presenter: Bei-Bei Chen
Session: Poster session 18
1505P - Exploratory biomarker analysis of the NEONAX trial for response prediction to perioperative (PO) and adjuvant (A) Gem-nabPac chemotherapy (CTX) in resectable PDAC patients (rPDAC Pts)
Presenter: Anton Lahusen
Session: Poster session 18
1506P - ctDNA testing based on deep NGS predicts treatment efficacy and prognosis in advanced pancreatic cancer patients
Presenter: Tingting You
Session: Poster session 18
1507P - Revolutionizing clinical trials: Harnessing artificial intelligence for optimized phase III studies in pancreatic cancer
Presenter: Marie-Edith Bonneterre
Session: Poster session 18
1509P - Cytokines and ductal pancreatic adenocarcinoma: Exploring their relationship with prognosis and molecular subtypes
Presenter: Laura Gutierrez Sainz
Session: Poster session 18
1510P - Exploration of circulating free bacterial DNA as a biomarker for therapy response in metastatic and locally advanced pancreatic cancer patients treated with systemic chemotherapy
Presenter: Sai Surendran
Session: Poster session 18
1511P - The influence of intratumoral bacteria and peri-operative antibiotic treatment on the outcome of resected pancreatic cancer patients treated with adjuvant gemcitabine-based chemotherapy
Presenter: Steffen Ormanns
Session: Poster session 18
1513P - Impact of symptom and functional burden on survival in pancreatic ductal adenocarcinoma (PDAC)
Presenter: Omali Pitiyarachchi
Session: Poster session 18
1514P - A prospective, single-center, randomized, controlled, evaluator-blinded, feasibility clinical trial for efficacy and safety of a non-tissue destructive compact focused ultrasound system with neoadjuvant FOLFIRINOX in locally advanced or borderline resectable pancreatic cancer
Presenter: Jae Young Lee
Session: Poster session 18